U.S. WGS services market size 2025
$XX.XM
Total U.S. services market
Placeholder
Decision Overview
Whether and how Invivoscribe should enter the U.S. whole-genome sequencing services market in hematological malignancies. Forecast period 2025–2036.
U.S. WGS services market size 2036
$XX.XM
Placeholder
CAGR 2025–2036
XX.X%
Placeholder
Incremental opportunity
$XX.XM
Placeholder
Most commercially relevant opportunity
Genome-wide structural and copy-number characterisation in myeloid disease.
AML and MDS carry the clearest published clinical genome use, the densest cytogenetic workload and the strongest case for workflow consolidation.
Open Clinical Use & AdoptionPrincipal adoption constraint
Reimbursement position and interpretation burden, not analytical capability.
Laboratories can generate genome data today; sustained clinical use depends on coverage, turnaround and reporting capacity.
Open Business Case & Market AccessMost credible entry pathway
Research-use entry supporting laboratories and pharmaceutical programmes first.
An RUO position builds evidence and installed use while a clinical-diagnostic or companion-diagnostic route is validated.
Open Strategic Opportunity